Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1): a006189.

Article  PubMed  PubMed Central  Google Scholar 

Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546–54.

Article  CAS  PubMed  Google Scholar 

Dementia 2023 [updated 15 March 2023]. https://www.who.int/news-room/fact-sheets/detail/dementia.

Viscogliosi G, Marigliano V. Alzheimer’s disease: how far have we progressed? Lessons learned from diabetes mellitus, metabolic syndrome, and inflammation. J Am Geriatr Soc. 2013;61(5):845–6.

Article  PubMed  Google Scholar 

Judge D, Roberts J, Khandker RK, Ambegaonkar B, Black CM. Physician practice patterns associated with diagnostic evaluation of patients with suspected mild cognitive impairment and Alzheimer’s disease. Int J Alzheimer’s Dis. 2019;2019:4942562.

Google Scholar 

Briggs R, Kennelly SP, O’Neill D. Drug treatments in Alzheimer’s disease. Clin Med (Lond). 2016;16(3):247–53.

Article  PubMed  Google Scholar 

2022 Alzheimer's disease facts and figures. Alzheimer’s Dementia. 2022;18(4):700–89.

Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol. 2016;14(1):101–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.

Article  ADS  CAS  PubMed  Google Scholar 

Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.

Article  ADS  CAS  PubMed  Google Scholar 

Behl T, Kaur I, Fratila O, Brata R, Bungau S. Exploring the potential of therapeutic agents targeted towards mitigating the events associated with amyloid-β cascade in Alzheimer’s disease. Int J Mol Sci. 2020;21(20):7443.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grossberg GT, Tong G, Burke AD, Tariot PN. Present algorithms and future treatments for Alzheimer’s disease. J Alzheimer’s Dis JAD. 2019;67(4):1157–71.

Article  PubMed  Google Scholar 

Pinheiro L, Faustino C. therapeutic strategies targeting amyloid-β in Alzheimer’s disease. Curr Alzheimer Res. 2019;16(5):418–52.

Article  CAS  PubMed  Google Scholar 

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lacorte E, Ancidoni A, Zaccaria V, Remoli G, Tariciotti L, Bellomo G, et al. Safety and efficacy of monoclonal antibodies for Alzheimer’s disease: a systematic review and meta-analysis of published and unpublished clinical trials. J Alzheimers Dis. 2022;87(1):101–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097.

Article  PubMed  PubMed Central  Google Scholar 

Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:Ed000142.

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3(2):98–110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

Article  PubMed  Google Scholar 

Shim S, Yoon BH, Shin IS, Bae JM. Network meta-analysis: application and practice using Stata. Epidemiol Health. 2017;39: e2017047.

Article  PubMed  PubMed Central  Google Scholar 

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, et al. ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, et al. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimer’s Res Ther. 2018;10(1):96.

Article  Google Scholar 

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6.

Article  ADS  CAS  PubMed  Google Scholar 

Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(10):1015–24.

Article  PubMed  PubMed Central  Google Scholar 

Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimer’s Res Ther. 2016;8(1):18.

Article  Google Scholar 

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–72.

Article  CAS  PubMed  Google Scholar 

Brashear HR, Ketter N, Bogert J, Di J, Salloway SP, Sperling R. Clinical evaluation of amyloid-related imaging abnormalities in bapineuzumab phase III studies. J Alzheimer’s Dis JAD. 2018;66(4):1409–24.

Article  CAS  PubMed  Google Scholar 

Nakamura T, Fujikoshi S, Funai J, Matsumura T. Disease-modifying effect of solanezumab evaluated by delayed-start analysis in a Japanese subpopulation with mild Alzheimer’s disease. Neurol Clin Neurosci. 2017;5(5):141–9.

Article  CAS  Google Scholar 

Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, et al. Donanemab (LY3002813) phase 1b study in Alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimer’s Dis. 2021;8(4):414–24.

CAS  Google Scholar 

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early alzheimer’s Disease. N Engl J Med. 2021;384(18):1691–704.

Article  CAS  PubMed  Google Scholar 

Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79(11):1113–21.

Article  PubMed  PubMed Central  Google Scholar 

Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O’Gorman J, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimer’s Dementia (New York, N Y). 2016;2(3):169–76.

Article  PubMed  Google Scholar 

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.

Article  PubMed  Google Scholar 

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198–207.

Article  PubMed  Google Scholar 

Landen JW, Cohen S, Billing CB Jr, Cronenberger C, Styren S, Burstein AH, et al. Multiple-dose ponezumab for mild-to-moderate Alzheimer’s disease: safety and efficacy. Alzheimer’s Dementia (New York, N Y). 2017;3(3):339–47.

Article  PubMed  Google Scholar 

Lu M, Brashear HR. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous bapineuzumab: a single-ascending-dose study in patients with mild to moderate Alzheimer disease. Clin Pharmacol Drug Dev. 2019;8(3):326–35.

Article  CAS  PubMed  Google Scholar 

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–21.

Article  CAS  PubMed  Google Scholar 

Brody M, Liu E, Di J, Lu M, Margolin RA, Werth JL, et al. A phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer’s disease. J Alzheimer’s Dis JAD. 2016;54(4):1509–19.

Article  CAS  PubMed